Bristol-Myers Squibb Company (BMY) Moat Analysis

Erosion risks

• Generic entry timing (U.S. 2028; EU earlier in some countries)
• Government pricing rules and payer rebate pressure
• Clinical differentiation vs rival DOACs

Leading indicators

• ANDA/court docket updates for apixaban patents
• Net price (gross-to-net) trend for Eliquis
• EU generic penetration by country

Counterarguments

• DOAC choice is heavily influenced by payer formularies; PBMs can switch preferred products quickly
• Competitors can win share via contracting or new data in key indications

Erosion risks

• Loss of exclusivity for older IO assets (e.g., Yervoy)
• Clinical trial outcomes or label changes favoring competitors
• Next-generation IO modalities (bispecifics, ADC combos) shifting standards of care

Leading indicators

• New indications/label expansions and guideline updates
• Competitor trial readouts in key tumor types
• Price/rebate trend in oncology channels

Counterarguments

• Competitors with larger IO franchises can outspend or out-contract in oncology
• Rapidly evolving standards of care can flip market share on new data

Erosion risks

• Manufacturing quality failures, recalls, or regulatory enforcement
• Input constraints (specialized materials) or single-source dependencies
• Biologics biosimilar manufacturing capabilities catching up

Leading indicators

• FDA/EMA inspection outcomes and warning letters
• Capacity expansion milestones for biologics/cell therapy sites
• Reported supply disruptions or backorders

Counterarguments

• Most large pharma can access biologics manufacturing via internal plants or CMOs; advantage may be incremental
• Supply capability does not guarantee clinical differentiation or market share

Erosion risks

• Generic/biosimilar entry accelerating price and volume declines
• Newer modalities in myeloma (CAR-T, bispecifics) displacing IMiDs
• Payer pressure as multiple alternatives exist

Leading indicators

• Generic launch/volume data for lenalidomide and pomalidomide
• NCCN/ESMO guideline shifts and new trial readouts
• Net sales trajectory by product (Revlimid vs Reblozyl mix)

Counterarguments

• Much of the franchise is already in decline due to generics; moat may be mostly harvested, not defended
• Treatment paradigms are moving to newer modalities where BMS is not the leader

Erosion risks

• Authorized Orencia IV biosimilar entry upon approval and subcutaneous entry as early as February 2028
• Government-set Medicare pricing for Orencia beginning in 2028
• High competition and payer step edits in immunology

Leading indicators

• Biosimilar filings and litigation outcomes for abatacept
• Sotyktu prescription growth vs rival oral/systemic agents
• Formulary positioning in commercial and Medicare channels

Counterarguments

• Immunology markets are highly rebate-driven; payer decisions can override clinical preference
• Multiple differentiated alternatives reduce the durability of any one brand's position

Erosion risks

• Manufacturing deviations causing supply interruptions
• Competitors scaling superior CAR-T products
• Input shortages (vectors, specialized materials)

Leading indicators

• Facility buildout/expansion milestones and throughput
• Regulatory inspection outcomes
• Commercial CAR-T capacity utilization and lead times

Counterarguments

• Contract manufacturers can lower entry barriers over time
• Clinical superiority, not manufacturing alone, determines winner-take-most in CAR-T

Erosion risks

• Patent litigation losses or earlier-than-expected generic entry
• Rapid competitive innovation in specialty niches
• Reimbursement tightening for high-cost specialty therapies

Leading indicators

• Patent/SPC litigation updates and Orange Book challenges
• New specialty product launches and trial readouts
• Coverage and prior-authorization changes

Counterarguments

• Specialty markets can shift quickly with new data; exclusivity does not ensure dominance
• Regulators and payers may limit uptake even when IP is intact